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Abstract A 2-year-old female with Hurler syndrome (muco-
polysaccharidosis type 1) died suddenly within 3 months of
successful unrelated fully matched cord blood transplant,
having received weekly enzyme replacement therapy (ERT)
prior to transplant. Though an infectious aetiology was
clinically suspected to be the cause of her unanticipated acute
deterioration and untimely demise, autopsy findings suggested
that a combination of pre-existing but sub-clinical Hurler
related cardiopulmonary pathology and superimposed trans-
plant related pulmonary venopathy as the basis of her death.
This case highlights the limitations of ERT in ameliorating
cardiorespiratory disease and the failure of standard pre-
transplant investigations to detect significant abnormality
related to her underlying condition. It also reinforces the
importance of autopsy in explaining unanticipated events.
Introduction
Mucopolysaccharidosis type I (MPS I) or Hurler syndrome
(HS) is an autosomal recessive metabolic disorder caused by
the deficiency of a-l-iduronidase, resulting in the accumula-
tion of substrates including heparin and dermatan sulphate.
This accretion leads to characteristic facial features,
hepatosplenomegaly, skeletal abnormalities, multi-organ
dysfunction and progressive mental retardation. Allogeneic
haematopoietic stem cell transplantation (HSCT) is the
standard of care for patients with this condition (Krivit
et al. 2005; Boelens et al. 2007; Prasad et al. 2010) and
results in amelioration of many of the symptoms associated
with this disorder and stabilisation of neuropsychological
status but has limited impact on skeletal and corneal
abnormalities (Peters and Steward, 2003; Aldenhoven et al.
2008). There are now robust data to support the contention
that transplantation in infancy offers superior outcomes
(Muenzer et al. 2009; Boelens et al. 2007), and the possibility
of newborn screening programmes is a subject of current
debate (Marsden and Levy 2010). HSCT, ideally before 18
months of age, while intellectual function is still preserved,
has been recommended by some (Peters and Steward 2003),
while a recently published European consensus document
favours transplant by 2.5 years (de Ru et al. 2011). Weekly
infusions of recombinant enzyme replacement therapy (ERT)
have been shown to reduce morbidity, particularly in relation
to cardiorespiratory function, prior to transplant (Cox-Brink-
man et al. 2006; Wiseman et al. 2012) and is now standard
practice in many major centres. This report documents the
unexpected course of events following HSCT in a toddler
whose peri-transplant course was uneventful.
Case Report
A female infant, born to non-consanguineous parents,
displaying many of the features of Hurler syndrome, was
eventually diagnosed at 23 months with MPS1, genotype
W402X/W402X, a known mutation generating a
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premature stop codon and associated with no enzyme
production. She was asymptomatic from a cardiorespira-
tory perspective with serial normal blood pressure meas-
urements and was commenced on weekly ERT while
awaiting HSCT. Standard pre-transplant assessment
included 2D and M mode echocardiography on three
separate occasions, all of which revealed normal left
ventricular function and no evidence of valvular incompe-
tence. Respiratory status was also unremarkable. Follow-
ing 4 months of weekly ERT (100 U/kg) while awaiting
transplant, she underwent an uneventful HLA identical
(10/10) matched unrelated cord blood transplant (CBT)
following busulfan (with pharmacokinetic monitoring),
fludarabine and ATG conditioning with cyclosporine and
methylprednisolone as GVHD prophylaxis. Her transplant
course was uneventful with normal organ function, no
significant infection and without graft versus host disease.
Complete donor leucocyte engraftment was documented at
28 days post transplant using molecular analysis of donor/
recipient discriminatory short tandem repeats. She
remained well and asymptomatic on close surveillance
following discharge on prophylactic cotrimoxazole, peni-
cillin, acyclovir and itraconazole. On D + 86, she
presented with a 5-day history of dry cough; on clinical
examination, she was afebrile, O2 saturation was at 60 %
in room air and chest x-ray revealed bilateral pulmonary
infiltrates. No conduction abnormality or arrhythmia was
documented on cardiac monitoring. She was commenced
on broad-spectrum antibiotics but deteriorated rapidly
over the succeeding 2–3 h, had a cardiorespiratory arrest
and failed to respond to resuscitation. The clinical
impression at the time of her death was of a respiratory
tract infection, probably viral in origin. Pre-mortem
nasopharyngeal aspirate was negative for all respiratory
pathogens.
A limited post-mortem examination, confined to the
chest at parent’s request, identified significant pulmonary
and cardiac disease. The lungs showed no evidence of any
infectious process on histological examination or in micro-
biological investigations including both culture and sero-
logical testing. The underlying airway architecture was
unremarkable but there was a range of vascular pathology.
Pulmonary arteries exhibited a patchy but often profound
vasculopathy with marked intimal wall thickening without
aneurysmal, plexiform or necrotising changes (Fig. 1).
There was also evidence of a venopathy with pronounced
endothelial swelling and atypia in a majority of pulmonary
veins associated with fibroproliferative changes and attemp-
ted recanalisation (Fig. 2). Peri-arteriolar foreign body giant
cells and foreign body giant cell granulomas without
refractile material were also detected and occasional large
arteries showed eccentric endothelial cushions with choles-
terol clefts present while another showed an almost
occlusive thrombo-embolus with abundant cholesterol
debris. The lung sections also showed fibrin in some
alveoli and there were multiple areas of microscopic acute
pulmonary haemorrhage.
Gross examination of the heart showed pericardial,
endocardial and valvular thickening (Fig. 3). Histological
examination confirmed conspicuous myxoid and fibromyx-
oid change in atrio-ventricular valve leaflets. There was
profound endocardial thickening, particularly in the atrium,
and areas of interstitial fibrosis were seen most notably in
papillary muscles of the left ventricle. There was a
profound coronary arteriopathy with substantial fibro-
intimal thickening (Fig. 4). Connective tissue stains
confirmed the presence of a vasculopathy and alcian blue
histochemistry confirmed the presence of myxoid intersti-
tial infiltrate within the valvular, endocardial and coronary
arterial structures.
Fig. 1 Section of lung containing pulmonary artery branches with
marked myointimal thickening
Fig. 2 Section of lung showing pulmonary vein with fibro-oblitera-
tive venopathy
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The findings suggested that a combination of pre-
existing but sub-clinical Hurler related cardiopulmonary
pathology and superimposed transplant related pulmonary
venopathy formed the basis of the patient’s abrupt clinical
deterioration and death.
Discussion
Cardiac disease in MPS 1 has a prevalence and severity
believed to be in the range of 60–100 % of those studied
and ranges from severe dilated cardiomyopathy presenting
within days or weeks of birth to identification of thickened
and incompetent cardiac valves in otherwise asymptomatic
individuals (Leal et al. 2010; Braunlin et al. 2011; Wiseman
et al. 2012). While valvular abnormalities and coronary
artery disease are most frequently documented, vascular
changes in great vessels and conduction abnormalities have
also been described. Transthoracic echocardiography and
12-lead ECG remain the standard methods used to assess
cardiac status in these patients, and serial monitoring,
following successful transplantation, has proved a reliable
indicator of cardiac function in the vast majority of patients.
Other more invasive techniques, including transoesopha-
geal echocardiography, cardiac MRI and coronary angiog-
raphy, are rarely indicated and are not without risk in this
unique group of patients and may also underestimate the
extent of disease.
Enzyme replacement therapy (ERT), usually commenced
once a diagnosis is made and continued until there is
evidence of sustained engraftment, has revolutionised the
management of dilated cardiomyopathy in infancy (Hirth
et al. 2007; Wiseman et al. 2012) with many other centres
reporting anecdotal evidence of improvement in shortening
fraction and subsequent uneventful HSCT, together with
alleviation of upper respiratory symptoms. Valvular
thickening, on the other hand, appears irreversible and
may even progress (Braunlin et al. 2003; Malm et al. 2008),
reflecting the relative avascularity of these structures. While
some authors suggest that the status of coronary ostia may
be improved following successful transplantation (Braunlin
et al. 2001), others have not supported this observation
(Yano et al. 2009).
The impact of cardiac disease on survival following
bone marrow transplantation is also disputed. In a study
carried out in Minnesota comprising 74 patients with MPS
1 undergoing HSCT, the overall survival post transplant
was 63 % and 53 % at 1 and 5 years, respectively. An
assessment of pre-transplant risk factors found no clear link
to cardiac status. However, patients with pulmonary
complications were associated with reduced survival. Of
the 33 patients who died, the largest proportion died of
infection (Orchard et al. 2010).
Pulmonary veno-occlusive disease (PVOD) has been
previously documented following HSCT, usually in associ-
ation with haematological malignancies (Barker et al. 2003;
Montani et al. 2010). It is thought that the greatest risk
factor for the development of PVOD is endothelial injury
from cytotoxic chemotherapy and irradiation. Several
reports indicate that patients with MPS 1 may have a
higher likelihood of pulmonary complications such as
alveolar haemorrhage than patients of similar age trans-
planted for other diseases (Gassas et al. 2003; Orchard et al.
2010). Hepatic VOD has been well documented following
HSCT (Barker et al. 2003; Copell et al. 2010; Corbacioglu
et al. 2012), and the risk is increased when busulphan is
used as conditioning agent (Vassal et al. 1996; Corbacioglu
et al. 2012); PVOD is more difficult to document as lung
biopsy is rarely undertaken. It is worth noting that
Fig. 3 Left side of the heart at autopsy showing thickened mitral
valve leaflets with distinct nodularity of the free margins of the cusps
Fig. 4 Section of the proximal left anterior descending coronary
artery showing marked intimal thickening
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pharmacokinetic monitoring of intravenous busulphan was
well within the therapeutic range in this patient.
In conclusion, the fulminant course experienced by our
patient is a sobering reminder that standard pre-transplant
evaluation may fail to detect the true extent of cardiorespi-
ratory pathology. This experience raises the question of
whether the recently recommended upper age limit of 2.5
years for HSCT in this condition (de Ru et al. 2012) is
appropriate for patients with the more severe genotype as
was the case in this particular patient. Consideration must
also be given to the incorporation of non-busulphan
conditioning regimens for this high-risk cohort of patients.
This case report also reinforces the role that autopsy can
play in explaining unanticipated events for both family and
clinical staff, providing information that continues to
impact on the shape of future practice.
Take-Home Message
Standard pre-transplant workup may underestimate the
extent of cardiorespiratory disease in Hurler syndrome
which may be compounded by current conditioning
regimens.
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